Blood cancers, Cell type, Hodgkin lymphoma, Lymphoma
Results
Phase 2
This trial was to see if a combination of chemotherapy drugs called VEPEMB worked as well as ABVD chemotherapy for Hodgkin lymphoma.
One of the most common treatments for Hodgkin lymphoma is a combination of chemotherapy called ABVD. This is doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine. Because the treatment is very intensive, the side effects can be quite bad. Older people often need to have lower doses of drugs, or sometimes aren’t well enough to have this treatment at all.
Doctors hoped a new combination of drugs called VEPEMB would be as good as ABVD but cause fewer side effects. VEPEMB is a combination of the chemotherapy drugs vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone and bleomycin, and the steroid prednisolone. They hoped it would be better than ABVD for people over 60 years old. The aims of this trial were to find out
More about the side effects of VEPEMB
How good VEPEMB was for people over 60 years old with Hodgkin lymphoma
Recruitment start: 1 September 2004
Recruitment end: 30 August 2009
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Stephen Proctor
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Marrow & Stem Cell Transplant 2000
NIHR Clinical Research Network: Cancer
SHIELD Study Group
The Newcastle upon Tyne Hospitals NHS Foundation Trust
This is Cancer Research UK trial number CRUKE/03/020.
Last reviewed: 9 July 2012
CRUK internal database number: 558
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
